Amikacin (A.M.K)

Subscribe to Selected New Research on Amikacin

1251 relevant articles (170 outcomes, 183 trials/studies) found for this Drug

Description: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.

Also Known As:

A.M.K; Amikacin Sulfate; Amikacina Medical; Amikacina Normon; Amikafur; Amikalem; Amikason's; Amikayect; Amikin; Amiklin; Amukin; Apothecon Brand of Amikacin Sulfate; BB-K 8; BB-K8; Biclin; Biklin; Bristol-Myers Squibb Brand of Amikacin Sulfate; Collins Brand of Amikacin Sulfate; Cryopharma Brand of Amikacin Sulfate; Fustery Brand of Amikacin Sulfate; Galen Brand of Amikacin Sulfate; Gamikal; Grossmann Brand of Amikacin Sulfate; Kanbine; Lemery Brand of Amikacin Sulfate; Mead Johnson Brand of Amikacin Sulfate; Medical Brand of Amikacin Sulfate; Norman Brand of Amikacin Sulfate; Oprad; Pisa Brand of Amikacin Sulfate; Rovi Brand of Amikacin Sulfate; Son's Brand of Amikacin Sulfate; Yectamid; BB K 8; BB K8; BBK 8; BBK8; Bristol Myers Squibb Brand of Amikacin Sulfate; Medical, Amikacina; Normon, Amikacina; Sulfate, Amikacin; D-Streptamine, O-3-amino-3-deoxy-alpha-D-glucopyranosyl-(1-6)-O-(6-amino-6-deoxy-alpha-D-glucopyranosyl-(1-4))-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)-

Relationship Network

Drug Context: Research Results

Carbohydrates: 2949

Glycosides: 342

Aminoglycosides: 1078

Kanamycin: 678

Amikacin: 1251

1-N-acylkanamycin B: 1

3',4'-dideoxyamikacin

3'-deoxyamikacin

4'-deoxy-6'-N-methylamikacin

6''-chloro-6''-deoxyamikacin

6'-N-acetimidoylamikacin

6'-N-formimidoylamikacin

butikacin

Experts

1.	Rong, Xin-Zhou: 3 articles (02/2008 - 02/2007)
2.	Zhang, Tao: 3 articles (02/2008 - 02/2007)
3.	Hua, Rong: 3 articles (02/2008 - 02/2007)
4.	Yang, Rong-Hua: 3 articles (02/2008 - 02/2007)
5.	Kotaska, K: 2 articles (08/2008 - 01/2004)
6.	Ceyhan, M: 2 articles (06/2008 - 04/2001)
7.	Chaudhary, Manu: 2 articles (05/2008 - 01/2008)
8.	Varughese, Lallu: 2 articles (05/2008 - 01/2008)
9.	Shrivastava, Sanjay Mohan: 2 articles (05/2008 - 01/2008)
10.	Sehgal, Rajesh: 2 articles (05/2008 - 01/2008)

Related Diseases

1.	Infection 05/01/1984 - "In vitro susceptibility tests of synergy were predictive of successful therapy whenever the antibiotic concentrations (free and total) at the infection site exceeded the MBC for both the aminoglycoside alone and the beta-lactam when tested in combination with amikacin." 04/01/1990 - "Correlation of these data with amikacin pharmacokinetic data in volunteers indicated that a daily dose of 15 mg/kg may be effective in the treatment of Escherichia coli and Enterobacter cloacae infections" 07/15/1985 - "Amikacin is effective in pediatric infections and is well tolerated by children" 05/01/1985 - "Amikacin has been found to be effective against pathogens associated with uterine infections in the mare and the woman, but its efficacy has not been studied in the cat" 07/01/1978 - "Amikacin is effective against susceptible pathogens in bone and joint infections and is a reasonable choice when aminoglycoside antibiotic is indicated." Order ALL the reference details at left...
2.	Neoplasms (Cancer) 05/01/1991 - "This study in 12 cancer treatment centres across the United States was designed to evaluate the potential for increased resistance to amikacin with unrestricted use" 06/30/1986 - "Several hospitals (Strong Memorial Hospital, University of Maryland Cancer Center, and Minneapolis Veterans Administration Medical Center) have reported either no significant change or a decrease in resistance to amikacin when it was the most frequently used aminoglycoside" 11/01/1982 - "Pharmacokinetic principles were used to determine amikacin doses for granulocytopenic cancer patients on empirical antibiotic regimens, and audiometry was used to determine the effect of this treatment on auditory acuity" 11/01/1982 - "Ototoxicity and pharmacokinetically determined dosages of amikacin in granulocytopenic cancer patients." 08/01/1982 - "Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients." Order ALL the reference details at left...
3.	Fever (Fevers) 09/01/1996 - "BACKGROUND: The efficacy of single daily dose of amikacin has been recently demonstrated in neutropenic children with fever" 09/01/1996 - "Clinical, pharmacokinetic and therapeutic study of amikacin with single daily dose and in combination in neutropenic children with fever]" 11/01/1993 - "This study reports on the use of an easily applied Bayesian forecasting programme (OPT; Clydesoft) to predict amikacin dose requirements in 10 patients with haematological disease and neutropenic fever" 08/01/2001 - "Effect of fever on pharmacokinetics and dosage regimen of intramuscularly administered amikacin in goats." 01/01/1996 - "Amikacin in single daily doses in children with fever]" Order ALL the reference details at left...
4.	Neutropenia 01/01/2002 - "The use of EIAA in children with febrile neutropenia has been evaluated primarily with amikacin" 04/01/1996 - "The pharmacokinetics of Amikacin were studied in 56 febrile episodes for 45 patients with severe neutropenia while using the USCPack PC Clinical Programs for adaptive control of their dosage regimens [223 drug levels]" 03/01/2008 - "Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections" 11/01/1998 - "The use of amikacin 20 mg/kg daily delivered in a single daily dose is recommended for immunocompromised pediatric patients with fever and neutropenia, in spite of the measured pharmacokinetic differences." 03/01/1982 - "Amikacin sulfate was given to 21 febrile children with neutropenia and cancer for 9 +/- 3 days" Order ALL the reference details at left...*
5.	Bacteremia 06/01/1977 - "The efficacy of amikacin treatment of 152 patients with bacteremia was reviewed from case reports submitted by 53 investigators" 08/01/1997 - "Vancomycine and amikacin combined is an effective antibiotic combination used in the treatment of serious Gram-positive bacteremia in childhood" 04/01/1992 - "Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside." 05/01/1978 - "The emergence of resistance to amikacin was noted in one patient treated with amikacin in whom Serratia bacteremia persisted" 06/01/1977 - "Review of 152 patients with bacteremias treated with amikacin." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Ceftazidime (Fortum)
2.	Gentamicins (Gentamicin)
3.	Ciprofloxacin (Cipro)
4.	Imipenem
5.	Tobramycin (Nebcin)
6.	Piperacillin
7.	Anti-Bacterial Agents (Antibiotics)
8.	meropenem (Merrem)
9.	Cefotaxime (Kendrick)
10.	cefepime (Maxipime)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Renal Dialysis (Hemodialysis)
3.	Intensive Care (Surgical Intensive Care)
4.	Aftercare (After-Treatment)
5.	Surgical Decompression

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 13887 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>